Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage - PubMed (original) (raw)

Comparative Study

. 2007 Mar 15;13(6):1720-5.

doi: 10.1158/1078-0432.CCR-06-2467.

Vincent Hupertan, David R Yates, James W F Catto, Ishtiaq Rehman, Mark Meuth, Sylvie Ricci, Roger Lacave, Géraldine Cancel-Tassin, Alexandre de la Taille, François Rozet, Xavier Cathelineau, Guy Vallancien, Freddie C Hamdy, Olivier Cussenot

Affiliations

• PMID: 17363525
• DOI: 10.1158/1078-0432.CCR-06-2467

Comparative Study

Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage

Morgan Rouprêt et al. Clin Cancer Res. 2007.

Abstract

Purpose: The diagnosis of localized prostate cancer is difficult due to a lack of cancer-specific biomarkers. Many patients require repeat prostate biopsies to diagnose the disease. We investigated whether aberrant promoter hypermethylation in prostatic fluid could reliably detect prostate cancer.

Experimental design: Urine samples were collected after prostate massage from 95 patients with localized prostate cancer undergoing radical prostatectomy (63 pT(1), 31 pT(2), and 1 pT(3)) and from 38 control patients. Ten genes (GSTP1, RASSF1a, ECDH1, APC, DAPK, MGMT, p14, p16, RARbeta2, and TIMP3) were investigated using quantitative real-time methylation-specific PCR. Receiver operator curves were generated.

Results: The frequency of gene methylation ranged from 6.3% (p14) to 83.2% (GSTP1) in prostate cancer patients. At least one gene was hypermethylated in 93% of cancer patients. The specificity of methylation was 0.74. Methylation was significantly more frequent (P < 0.05) in cancer than control patients for all genes except p14 and p16. According to receiver operator curve analysis, the four-gene combination of GSTP1 (0.86), RASSF1a (0.85), RARbeta2 (0.80), and APC (0.74) best discriminated malignant from nonmalignant cases. The sensitivity and accuracy of this four-gene set were 86% and 89%, respectively.

Conclusions: The presence of aberrant methylation in urinary cells obtained after prostate massage is significantly associated with prostate cancer. A panel of four genes could stratify patients into low and high risk of having prostate cancer and optimize the need for repeat prostatic biopsies.

PubMed Disclaimer

Similar articles

• Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
  Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W, Westra WH, Sidransky D. Hoque MO, et al. J Clin Oncol. 2005 Sep 20;23(27):6569-75. doi: 10.1200/JCO.2005.07.009. J Clin Oncol. 2005. PMID: 16170165
• Multigene methylation analysis for detection and staging of prostate cancer.
  Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Enokida H, et al. Clin Cancer Res. 2005 Sep 15;11(18):6582-8. doi: 10.1158/1078-0432.CCR-05-0658. Clin Cancer Res. 2005. PMID: 16166436
• A quantitative promoter methylation profile of prostate cancer.
  Jerónimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D. Jerónimo C, et al. Clin Cancer Res. 2004 Dec 15;10(24):8472-8. doi: 10.1158/1078-0432.CCR-04-0894. Clin Cancer Res. 2004. PMID: 15623627
• Molecular detection of prostate cancer: a role for GSTP1 hypermethylation.
  Henrique R, Jerónimo C. Henrique R, et al. Eur Urol. 2004 Nov;46(5):660-9; discussion 669. doi: 10.1016/j.eururo.2004.06.014. Eur Urol. 2004. PMID: 15474280 Review.
• Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract.
  Phé V, Cussenot O, Rouprêt M. Phé V, et al. BJU Int. 2009 Oct;104(7):896-901. doi: 10.1111/j.1464-410X.2009.08696.x. Epub 2009 Jun 12. BJU Int. 2009. PMID: 19522860 Review.

Cited by

• Aberrant gene methylation in the peritoneal fluid is a risk factor predicting peritoneal recurrence in gastric cancer.
  Hiraki M, Kitajima Y, Sato S, Nakamura J, Hashiguchi K, Noshiro H, Miyazaki K. Hiraki M, et al. World J Gastroenterol. 2010 Jan 21;16(3):330-8. doi: 10.3748/wjg.v16.i3.330. World J Gastroenterol. 2010. PMID: 20082478 Free PMC article.
• DNA Methylation-Mediated Downregulation of DEFB1 in Prostate Cancer Cells.
  Lee J, Han JH, Jang A, Kim JW, Hong SA, Myung SC. Lee J, et al. PLoS One. 2016 Nov 11;11(11):e0166664. doi: 10.1371/journal.pone.0166664. eCollection 2016. PLoS One. 2016. PMID: 27835705 Free PMC article.
• 6-gene promoter methylation assay is potentially applicable for prostate cancer clinical staging based on urine collection following prostatic massage.
  Nekrasov KA, Vikarchuk MV, Rudenko EE, Ivanitskiy IV, Grygorenko VM, Danylets RO, Kondratov AG, Stoliar LA, Sharopov BR, Kashuba VI. Nekrasov KA, et al. Oncol Lett. 2019 Dec;18(6):6917-6925. doi: 10.3892/ol.2019.11015. Epub 2019 Oct 29. Oncol Lett. 2019. PMID: 31807193 Free PMC article.
• Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis.
  Wu T, Giovannucci E, Welge J, Mallick P, Tang WY, Ho SM. Wu T, et al. Br J Cancer. 2011 Jun 28;105(1):65-73. doi: 10.1038/bjc.2011.143. Epub 2011 Jun 7. Br J Cancer. 2011. PMID: 21654682 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal